{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-216147","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.411624+00:00","generated_at":"2026-06-24T02:04:51.978572+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Revolution Medicines Q2 net loss $61.2M; advances first two RAS(ON) inhibitors into clinic","bullets":["Net loss $61.2M in Q2 2022 vs $44.3M in Q2 2021; revenue from Sanofi collab $9.1M.","Cash, equivalents and securities $461.4M at June 30, 2022; July public offering raised $264.5M gross.","Updated FY 2022 GAAP net loss guidance to $260-280M; stock-based comp $30-35M.","First patient dosed in Phase 1/1b trial of RAS(ON) inhibitor RMC-6236; site activation for RMC-6291 underway.","Appointed Lorence Kim (ex-Moderna, Goldman Sachs) and Sushil Patel (ex-Genentech) to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-216147","json":"https://secwatch.observer/filing/0001193125-22-216147.json","markdown":"https://secwatch.observer/filing/0001193125-22-216147.md","text":"https://secwatch.observer/filing/0001193125-22-216147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000119312522216147/0001193125-22-216147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000119312522216147/d348230d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:04:51.978572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}